DA-302168S

Phase 2Small molecule

CChendu DIAO Pharmaceutical Group CO., LTD.

DA-302168S is one of 79 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusNot yet recruiting

OverweightActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Not yet recruiting

OverweightPhase 2

Active, not recruiting

Competition

Competitive Landscape

145 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

5 2

Maridebart Cafraglutide

Amgen

Phase 3

3 3

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

3 4

GZR4

GGan and Lee Pharmaceuticals, USA

Phase 3

5 5

Elecoglipron

AstraZeneca

Phase 3

5 6

HM11260C

Hanmi Pharmaceutical Company Limited

Phase 3

3 7

NOVOLIN R

Novo Nordisk

Preclinical

1 8

Adenocard

Astellas

Preclinical

1 9

Dostinex

Golytely

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Overweight

NCT07877038

Q4 2027

Phase 3Recruiting

Overweight and Obesity

NCT07629544

Phase 2Not yet recruiting

Type 2 Diabetes Mellitus

NCT07755150

Clinical

Trials by Indication[1]

Overweight3 trials

A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

Completed·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT06541730·48 enrolled

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

Active, not recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 2·NCT06953063·240 enrolled

A Study to Evaluate the Pharmacokinetic Characteristics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Hepatic Impairment and in Those With Normal Hepatic Function

Not yet recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT07877038·32 enrolled

Tics2 trials

The Food Effect on Pharmacokinetics of DA-302168S

Completed·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT06534346·16 enrolled

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

Completed·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 1·NCT06534320·50 enrolled

Type 2 Diabetes Mellitus1 trial

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study Assessing the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes Mellitus.

Not yet recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 2·NCT07755150·272 enrolled

Overweight and Obesity1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Participants

Recruiting·CChendu DIAO Pharmaceutical Group CO., LTD.·Phase 3·NCT07629544·840 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DA-302168S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DA-302168S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DA-302168S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chendu DIAO Pharmaceutical Group CO., LTD. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChendu DIAO Pharmaceutical Group CO., LTD.

DA-302168S

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Trials by Indication[1]

Overweight3 trials

Tics2 trials

Type 2 Diabetes Mellitus1 trial

Overweight and Obesity1 trial

References

Drug Info

Quick Facts

Related News